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OBJECTIVE—Angiotensin (ANG) II interacts with insulin-
signaling pathways to regulate insulin sensitivity. The type 1
(AT1R) and type 2 (AT2R) receptors reciprocally regulate basal
perfusion of muscle microvasculature. Unopposed AT2R activity
increases muscle microvascular blood volume (MBV) and glucose
extraction, whereas unopposed AT1R activity decreases both. The
current study examined whether ANG II receptors modulate mus-
cle insulin delivery and sensitivity.
RESEARCH DESIGN AND METHODS—Overnight-fasted rats
were studied. In protocol 1, rats received a 2-h infusion of saline,
insulin (3 mU/kg/min), insulin plus PD123319 (AT2R blocker), or
insulin plus losartan (AT1R blocker, intravenously). Muscle MBV,
microvascular flow velocity, and microvascular blood flow (MBF)
were determined. In protocol 2, rats received 125I-insulin with or
without PD123319, and muscle insulin uptake was determined.
RESULTS—Insulin significantly increased muscle MBV and
MBF. AT2R blockade abolished insulin-mediated increases in
muscle MBV and MBF and decreased insulin-stimulated glucose
disposal by ~30%. In contrast, losartan plus insulin increased
muscle MBV by two- to threefold without further increasing
insulin-stimulated glucose disposal. Plasma nitric oxide increased
by .50% with insulin and insulin plus losartan but not with in-
sulin plus PD123319. PD123319 markedly decreased muscle in-
sulin uptake and insulin-stimulated Akt phosphorylation.
CONCLUSIONS—We conclude that both AT1Rs and AT2Rs reg-
ulate insulin’s microvascular and metabolic action in muscle. Al-
though AT1R activity restrains muscle metabolic responses to
insulin via decreased microvascular recruitment and insulin de-
livery, AT2R activity is required for normal microvascular
responses to insulin. Thus, pharmacologic manipulation aimed
at increasing the AT2R-to-AT1R activity ratio may afford the po-
tential to improve muscle insulin sensitivity and glucose metab-
olism. Diabetes 60:2939–2946, 2011
S
keletal muscle microvascular perfusion distribu-
tion is determined by precapillary terminal arte-
riolar tone. Dilating these arterioles increases
microvascular perfusion and expands the capil-
lary exchange surface area, whereas constriction leads to
the opposite (1,2). Microvascular insulin resistance and
dysfunction are closely related with metabolic insulin re-
sistance in diabetes (2–4). Insulin-mediated microvascular
recruitment precedes insulin-stimulated glucose uptake
in skeletal muscle (5), and blockade of insulin’s microvas-
cular action with Nv-nitro-L-arginine methyl ester (L-NAME)
decreases steady-state insulin-stimulated glucose disposal
by ~40% (5,6).
To act on muscle, insulin must first traverse the micro-
vasculature perfusing the muscle and then be transported
through the vascular endothelium into muscle interstitium.
Recent evidence suggests that altered muscle microvascu-
lar perfusion profoundly affects insulin delivery and action
in muscle (2). Many physiological factors regulate muscle
microvascular perfusion in vivo, including insulin, mixed
meals, and muscle contraction (7–12). Increased muscle
microvascular recruitment induced by muscle contraction
is associated with increased muscle insulin uptake (11).
The renin-angiotensin system (RAS) plays a central role
in maintaining hemodynamic stability (13,14), and angio-
tensin (ANG) II can interact with the insulin-signaling
pathways to regulate insulin sensitivity. In cultured cells,
ANG II acts via the ANG II type 1 receptor (AT1R) to impair
insulin actions (15–17). On the other hand, acutely raising
ANG II systemically improves insulin-stimulated muscle
glucose utilization in humans (18–20) and increases muscle
microvascular recruitment independent of blood pressure
changes in rodents (21). Both the AT1R and ANG II type 2
receptor (AT2R) are present on endothelial cells, vascular
smooth-muscle cells, and other vessel-associated cells
throughout skeletal muscle microcirculation (13,22,23).
ANG II stimulates cell proliferation and vasoconstriction via
the AT1Rs and promotes vasodilation through the AT2R
(24,25). We recently have reported that both the AT1Rs and
the AT2Rs significantly regulate basal microvascular tone
and glucose use by muscle (21). Although basal AT2R ac-
tivity increases muscle microvascular blood volume (MBV)
(an index of microvascular surface area and perfusion) and
glucose extraction, basal AT1R activity decreases both (21).
In the current study, we assessed whether ANG II
receptors modulate muscle insulin delivery and sensitivity
in vivo. Our results indicate that both AT1Rs and AT2Rs
regulate insulin’s microvascular and metabolic action in
muscle. Although AT1R activity restrains muscle metabolic
responses to insulin via decreased microvascular re-
cruitment and insulin delivery, AT2R activity is required
for normal microvascular responses to insulin.
RESEARCH DESIGN AND METHODS
Adult male SD rats (Charles River Laboratories, Wilmington, MA), weighing
220–320 g, were studied after an overnight fast. Rats were housed at 22 6 2°C,
on a 12-h light-dark cycle and fed standard laboratory diet and water ad libi-
tum prior to the study. After being anesthetized with pentobarbital sodium (50
mg/kg i.p.; Abbott Laboratories, North Chicago, IL), the rats were placed in
a supine position on a heating pad to ensure euthermia and intubated to
maintain a patent airway. The carotid artery and the jugular vein were can-
nulated with polyethylene tubing (PE-50; Fisher Scientific, Newark, DE) for
arterial blood pressure monitoring, arterial blood sampling, and various infu-
sions. After a 30- to 45-min baseline period to assure hemodynamic stability
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and a stable level of anesthesia, rats were studied under the following two
protocols.
Protocol 1. Five groups of rats were studied under this protocol (Fig. 1A).
Group 1 rats received an intravenous infusion of regular insulin (3 mU/kg/min)
for 120 min. Group 2 received systemic infusion of insulin (3 mU/kg/min) and
PD123319 (AT2R blocker, 50 mg/kg/min, started at25 min) for 120 min. Group 3
received a systemic infusion of insulin (3 mU/kg/min) for 120 min and PD123319
(50 mg/kg/min) 30 min after the initiation of insulin clamp. Group 4 received
a bolus intravenous injection of losartan (AT1R blocker, 0.3 mg/kg) 5 min before
the initiation of the insulin clamp. Arterial blood glucose was determined
every 10 min using an Accu-Chek Advantage glucometer (Roche Diagnostics,
Indianapolis, IN), and 30% dextrose (30% wt/vol) was infused at a variable rate
to maintain blood glucose within 10% of basal (26,27). Group 5 rats received a
saline infusion for 120 min.
Skeletal muscle microvascular blood volume (MBV), microvascular flow
velocity (MFV), and microvascular blood flow (MBF) were determined using
contrast-enhanced ultrasound, and femoral artery blood flow (FBF) was
measured using a flow probe (VB series, 0.5 mm; Transonic Systems), as
previously described (5,10,11,21). Plasma nitric oxide (NO) concentration was
determined at the beginning and the end of insulin infusion, as described
below. Rats then were killed and their gastrocnemius muscles freeze-clamped
for later measurement of Akt phosphorylation using Western blotting, as
previously described (26,27).
Protocol 2. Two groups of rats were studied under this protocol (Fig. 1B).
Group 1 received a continuous infusion of saline at 10 mL/min for 120 min.
Group 2 received a systemic infusion of PD123319 (50 mg/kg/min) for 120 min.
At 115 min, each rat received a bolus intravenous injection of 125I-insulin (1.5
mCi; Perkin Elmer, Boston, MA). Rats were killed at 120 min. Plasma and
gastrocnemius were obtained for determination of 125I-insulin uptake.
Throughout the study, mean arterial blood pressure (MAP) and heart rate
were monitored via a sensor connected to the carotid arterial catheter (Harvard
Apparatus, Holliston, MA, and AD Instruments, Colorado Springs, CO). Pen-
tobarbital sodium was infused at a variable rate to maintain steady levels of
anesthesia and blood pressure throughout the study. Losartan and PD123319
were obtained from Sigma Chemicals (St. Louis, MO). Losartan was given as
a bolus injection because of its longer plasma half-life (1.5–2.5 h for losartan
and 6–9 h for its active metabolite), whereas PD123319 was given as con-
tinuous infusion because of its much shorter half-life (22 min). At the doses
selected, neither losartan nor PD123319 significantly altered systemic blood
pressure (21,28) but had a profound effect on basal microvascular perfusion
(21). The plasma concentrations of losartan achieved were ~0.25 mg/mL (29)
and of PD123319 were ~3 3 1026 mol/L (30); values remained highly specific
for AT1R and AT2R, respectively. The investigation conformed to the Guide
for the Care and Use of Laboratory Animals, published by the National
Institutes of Health (publ. no. 85-23, revised 1996). The study protocols
were approved by the animal care and use committee of the University of
Virginia.
Measurement of plasma NO levels. Plasma NO levels were measured using
the 280i Nitric Oxide Analyzer (GE Analytical), according to the manufacturer’s
instructions. In brief, ice-cold ethanol was added into plasma samples at a ratio
of 2 to 1. The mixture was vortexed, kept at 0°C for 30 min, and then centrifuged
at ~14,000 rpm for 5 min. The supernatant then was used for NO analysis.
Muscle
125
I-insulin uptake. In protocol 2 studies, each rat received a bolus
intravenous injection of 1.5 mCi 125I-insulin 5 min prior to the end of the study.
This tracer amount of insulin does not increase systemic insulin concen-
trations and thus can be used to track the uptake of native insulin. We chose
this shorter duration of insulin exposure because of the short circulating half-
life (,5 min) for intact insulin (31). At the end of the experiment, a blood
sample was collected and each rat then was flushed with 120 mL ice-cold
saline (10 mL/min) via the carotid artery catheter. Gastrocnemius muscles
were dissected from the right hindlimbs. Protein-bound 125I in blood and
muscle samples were precipitated with 30% trichloroacetic acid and was ra-
dioactivity measured. Skeletal muscle insulin uptake was calculated using the
following formula: muscle insulin uptake = 125I-insulin in muscle (dpm/g dry
wt/5 min)/blood 125I-insulin (dpm/mL).
Statistical analysis. All data are presented as means 6 SEM. Statistical
analyses were performed with SigmaStat 3.1.1 software (Systat Software),
using one-way ANOVA or one-way repeated-measures ANOVA with post hoc
Holm-Sidak or Dunn analysis, where appropriate. A P value ,0.05 was con-
sidered statistically significant.
RESULTS
We have previously demonstrated that basal AT1R and
AT2R regulate muscle microvascular volume and glucose
use (21). Because the microvasculature plays an important
role in insulin delivery and substrate exchange between
the plasma and interstitial compartments, we first exam-
ined whether changes in AT1R and AT2R activities altered
insulin-mediated glucose disposal. As shown in Fig. 2,
injection of losartan had no effect on insulin-mediated
glucose disposal. On the other hand, PD123319 infusion,
given either immediately before or 30 min after the initiation
of insulin infusion, promptly attenuated insulin-stimulated
whole-body glucose disposal, and this effect was main-
tained during the entire 120 or 90 min of PD123319 in-
fusion (P , 0.02, ANOVA). At steady state, AT2R blockade
decreased the whole-body glucose disposal rate by ~30%
(P = 0.02 for both PD123319 groups). In saline-only rats, the
microvascular parameters did not change significantly dur-
ing the course of the study.
We have shown that basal AT1R tone restricts skeletal
muscle MBV, whereas basal AT2R activity increases mus-
cle MBV (21). We next examined whether selective stim-
ulation of the ANG II subtype receptors by endogenous
ANG II regulate insulin-mediated microvascular recruitment.
FIG. 1. Experimental protocols.
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Figure 3 shows the microvascular responses to insulin
infusion. Insulin infusion raised plasma insulin concen-
trations from 99 6 15 pmol/L to 685 6 151 pmol/L (n = 5,
P , 0.02). As expected, insulin increased both MBV and
MBF without altering MFV (Fig. 3). The addition of
PD123319 to insulin infusion promptly inhibited this
insulin-mediated increase in MBV and MBF and significantly
increased the MFV (Fig. 4). When PD123319 was given
before insulin infusion, insulin-induced increases in mus-
cle MBV and MBF were completely prevented. On the
other hand, infusion of PD123319 after insulin had already
significantly recruited muscle microvasculature (i.e., 30
min after insulin infusion) abrogated the insulin effects.
These changes did not seem to be secondary to changes in
blood pressure or total blood flow because both MAP and
FBF remained stable during the study (Table 1). Injection
of losartan 5 min prior to the initiation of insulin promptly
increased muscle MBV within 30 min, and the extent of
the increase (2.4- to 3.2-fold) was quite similar to what we
previously observed using losartan alone (21). The increase
in MBV lasted for the entire 120 min. Muscle MFV did not
change in the first 90 min but decreased at 120 min. As
a result, muscle MBF increased promptly at 30 min,
remained elevated at 60 min, and trended down afterward
(Fig. 5). Though MAP did not change, FBF decreased by
nearly 30% (P , 0.01) (Table 1).
The rapid attenuation of insulin-stimulated whole-body
glucose disposal and muscle microvascular recruitment by
PD123319 prompted us to further examine the impact of ANG
II receptor stimulation by endogenous ANG II on the insulin
effects on the vasculature (NO production) and muscle (Akt
phosphorylation). Both insulin and losartan increase micro-
vascular recruitment via a NO-dependent pathway (6,21). As
shown in Fig. 6A, 2 h of insulin infusion increased plasma NO
levels by nearly twofold (P , 0.01). Concurrent PD123319
infusion decreased insulin-mediated increases in plasma NO
levels by 37% (P , 0.04) to levels that were not significantly
different from the saline controls. On the other hand, losartan
injection had no significant impact on insulin-stimulated
NO production. Figure 6B shows insulin-stimulated Akt
phosphorylation in the skeletal muscle. Similar to the
pattern of plasma NO levels, insulin significantly increased
muscle Akt phosphorylation, and this effect was sup-
pressed back to the saline control level when PD123319
infusion was superimposed on insulin infusion. Again,
losartan had no effect on insulin-stimulated Akt phos-
phorylation in muscle. Muscle endothelial NO synthase
(eNOS) phosphorylation did not differ among all four
groups (Fig. 6C).
The above data clearly indicate that AT2R blockade
attenuates insulin-mediated muscle microvascular re-
cruitment, glucose disposal, and signaling. To this end,
we examined whether modulating the ANG II receptor
FIG. 2. AT2R antagonism attenuates insulin-mediated whole-body glucose disposal. Each rat received 2 h of insulin infusion in the absence
or presence of either PD123319 infusion (50 mg/kg/min, started at time25 or 30 min) or losartan injection (0.3 mg/kg i.v. at time25 min). n = 8–16.
*P < 0.02 (ANOVA).
FIG. 3. Insulin increases skeletal-muscle microvascular recruitment in
rats. A: Changes in muscle MBV. P < 0.03 (ANOVA). B: Changes in
muscle MFV. C: Changes in muscle MBF. P < 0.03 (ANOVA). n = 5–6.
Compared with basal level, *P < 0.05 and #P < 0.01.
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stimulation by endogenous ANG II would alter muscle in-
sulin delivery and uptake (protocol 2). As shown in Fig. 7,
infusion of PD123319 did not significantly alter 125I-insulin
degradation in the plasma (Fig. 7A). However, it decreased
muscle 125I-insulin content by nearly 50% (P , 0.05),
confirming a decreased muscle insulin uptake in the pres-
ence of AT2R blockade.
DISCUSSION
In humans, ANG II infusion acutely enhances insulin-
stimulated muscle glucose disposal (18–20). This was
suggested to be attributable to enhanced tissue perfusion,
although evidence for this was not available. We recently
have found that both the AT1R and AT2R exert potent basal
tonic effects on microvasculature in skeletal muscle (21).
FIG. 4. AT2R blockade attenuates insulin-mediated microvascular recruitment. PD123319 (50 mg/kg/min) was infused systemically either immediately
before (A–C) or 30 min after (D–F) the initiation of insulin clamp. A and D: Changes in muscle MBV. A: P = 0.86. D: P = 0.02 (ANOVA). B and E:
Changes in muscle MFV. B: P < 0.05. D: P < 0.02 (ANOVA). C and F: Changes in muscle MBF. n = 6–7 for each. Compared with basal level, *P < 0.05
and **P < 0.01; compared with 30 min, #P < 0.05 and ##P < 0.01.
TABLE 1
Changes in MAP and FBF in protocol 1 experiments
Basal 30 min 60 min 90 min 120 min
MAP (mmHg)
Insulin 106 6 3 107 6 5 107 6 2 108 6 3 108 6 2
Insulin + PD123319 96 6 5 92 6 6 93 6 4 104 6 6 96 6 6
Insulin + losartan 107 6 3 100 6 4 97 6 7 106 6 5 101 6 5
FBF (mL/min)
Insulin 0.78 6 0.06 0.78 6 0.05 0.82 6 0.04 0.84 6 0.07 0.94 6 0.07*
Insulin + PD123319 0.75 6 0.04 0.80 6 0.04 0.85 6 0.09 0.73 6 0.06 0.73 6 0.07
Insulin + losartan 0.83 6 0.10 0.75 6 0.10 0.70 6 0.09 0.68 6 0.08 0.60 6 0.07*
Data are means 6 SEM. n = 5–7. *Compared with basal (0 min), P , 0.01.
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Here, we show that both AT1R and AT2R regulate insulin’s
microvascular and metabolic actions in muscle. Although
the blockade of AT1R significantly increased muscle mi-
crovascular perfusion, it did not further enhance insulin-
stimulated whole-body glucose disposal, NO production,
and muscle Akt phosphorylation. In contrast, AT2R antag-
onism promptly attenuated muscle metabolic responses to
insulin, which was associated with decreased muscle in-
sulin uptake and insulin-mediated NO production and mi-
crovascular recruitment. Although we previously have
demonstrated that dual blockade of both AT1R and AT2R
had neutral effects on muscle microvascular recruitment
and basal glucose extraction, whether dual blockade alters
microvascular and muscle insulin sensitivity is unclear. In
addition, our observations may represent a combined pe-
ripheral and central effect because it is likely that both
losartan and PD123319 could exert central effects via
either penetrating the blood-brain barrier or acting on the
blood vessels in the central nervous system (28). An al-
ternative is to administrate these compounds locally into
the microvasculature via the epigastric artery (32). How-
ever, this would require abdominal incision, which further
stresses the animals, and prolonged infusions would likely
also raise systemic concentrations.
Similar to the previous reports (8,12,33–36), insulin po-
tently increased muscle MBV by 58–75%. Injection of los-
artan prior to the initiation of insulin infusion increased
muscle MBV by approximately two- to threefold (Fig. 5),
which is similar to what we observed previously with
losartan alone (21). Thus, there seems to be no additive
effects of losartan and insulin on muscle MBV. It is likely
that the large increase in MBV achieved with the losartan
injection may have masked the insulin effect. The large in-
crease in muscle MBV at 30 min without an increase in FBF
likely reflects a shift in flow distribution from nonnutritive
to nutritive microvascular beds (37). Of interest, MBF
trended down after 90 min, which was likely secondary to
the gradual decline in FBF and a decrease in MFV at 120
min. Whether these findings are caused by either losartan
alone or losartan plus insulin remain to be clarified because
MFV and MBF were not determined in our previous study
using losartan alone (21). Compared with increases induced
by insulin alone (Fig. 3), the increases in muscle MBV in-
duced by losartan and insulin combination was only sig-
nificantly higher at 30 min (P , 0.03), and increases in
muscle MBF were not statistically different between the
two groups. Thus, it is not surprising that the addition of
FIG. 5. Combined effects of insulin and AT1R blockade on skeletal-
muscle microvascular parameters. Losartan (0.3 mg/kg i.v.) was given 5
min before the initiation of insulin clamp. A: Changes in muscle MBV.
P < 0.001 (ANOVA). B: Changes in muscle MFV. P < 0.01 (ANOVA). C:
Changes in muscle MBF. P < 0.01 (ANOVA). n = 7. Compared with
0 min, *P < 0.05 and **P < 0.01.
FIG. 6. AT2R blockade decreases insulin-stimulated NO production and
skeletal muscle Akt phosphorylation. A: Changes in plasma NO levels.
n = 5–6. P = 0.005 (ANOVA). Compared with saline, *P< 0.01; compared
with insulin, #P < 0.05. B: Changes in muscle Akt phosphorylation. n =
7–9. P < 0.001 (ANOVA). Compared with saline, *P < 0.01; compared
with insulin, #P < 0.04. C: Changes in muscle eNOS phosphorylation.
n = 4. P > 0.05 (ANOVA). For gel images in B and C, they were from
different parts of the same gels with same exposure.
W. CHAI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, NOVEMBER 2011 2943
losartan to insulin did not further increase muscle insulin
action beyond what we saw with insulin alone because
insulin-mediated microvascular recruitment is tightly
coupled with insulin’s metabolic action.
AT2R has been associated with vasodilation in large
capacitance vessels, resistance arterioles, as well as the
microvasculature (21,23,38–41), likely via the bradykinin-
NO-cGMP signaling cascade because the AT2R antagonist
PD123319, the bradykinin receptor 2 antagonist icatibant,
and the NO synthase inhibitor L-NAME each independently
blocks this action (25,38,42,43). We previously have reported
that skeletal muscle precapillary arterioles are a major site of
AT2R action in vivo because blockade of the AT1R with
losartan causes a threefold increase in muscle MBV, whereas
blockade of the AT2R renders an ~80% reduction in muscle
MBV (21). Our current results confirmed that AT2R activity
also plays an important role in the regulation of insulin’s
microvascular and metabolic responses in muscle as well.
Indeed, PD123319 caused a prompt decrease in insulin-
mediated glucose disposal, which was associated with
abrogation of insulin-stimulated muscle microvascular re-
cruitment, NO production and muscle Akt phosphorylation,
and muscle insulin uptake. Thus, AT2Rs are important reg-
ulators of both basal microvascular tone and insulin delivery/
action in muscle via its effects on the microvasculature,
which is consistent with the current understanding that the
regulation of microvascular insulin delivery is a major rate-
limiting step in skeletal muscle insulin action (2,44–47).
It is important to distinguish between the acute effects
we observed and what might be going on when the RAS
already is at a higher level as occurs in obesity and
diabetes. Increased muscle microvascular perfusion in-
duced by muscle contraction is clearly associated with
increased muscle insulin uptake even in the presence of
high plasma free fatty acids (10,11). In humans, simple
obesity blunts insulin- and mixed-meal–stimulated muscle
microvascular recruitment (9,35). Likewise, in obese Zucker
rats, an animal model of metabolic syndrome and insulin
resistance, basal skeletal muscle MBV is decreased, which
is coupled with impaired insulin-mediated glucose disposal
and microvascular recruitment (48). Insulin uptake has not
been assessed in this model. However, treatment of the
Zucker diabetic fatty rats with the ACE inhibitor quinapril
restores insulin’s microvascular action and improves insulin-
mediated whole-body glucose disposal (49). Because the
cardiovascular RAS is upregulated in diabetes, which has
been implicated in the development of diabetic cardio-
vascular complications (7,13,24,50), blockade of the AT1R
and/or activation of the AT2R may help to improve insulin
delivery and sensitivity and potentially improve the car-
diovascular outcomes in patients with diabetes. Although
the current study revealed important modulatory roles of
ANG II subreceptors on insulin action under normal phys-
iology, whether the current findings can be extrapolated to
the insulin-resistant state is unclear and requires additional
studies.
We previously have shown in humans that physiologic
hyperinsulinemia increases muscle MBF solely by in-
creasing MBV without changing the MFV (8,35,36). Our
current study in rodents confirmed this lack of change in
MFV after insulin stimulation as well (Figs. 3 and 4). Al-
though the addition of losartan to the insulin infusion
caused a decrease in MFV at 120 min, superimposing the
PD123319 infusion not only promptly attenuated insulin-
stimulated MBV but it also increased muscle MFV. Be-
cause there was no change in total FBF, this increase in
MFV was likely secondary to the acute decrease in MBV.
Our finding that insulin increased plasma NO levels is
consistent with many previous reports demonstrating that
insulin causes vasodilation via the phosphatidylinositol
3-kinase/Akt/eNOS pathway (2,4–6,51). We previously have
demonstrated that losartan treatment led to microvascular
recruitment via the AT2R-NO–dependent mechanism be-
cause L-NAME treatment abolished losartan-induced in-
creases in MBV and glucose extraction (21). The increase
in plasma NO levels seen with combined losartan and insulin
treatment most likely reflects increased release of NO from
the endothelium secondary to endogenous ANG II stimula-
tion of the AT2R/B2R/eNOS pathway and insulin stimulation
of the phosphatidylinositol 3-kinase/Akt/eNOS pathway. The
NO release is less likely from skeletal muscle cells, because
they express predominantly AT1R (52), which activates
NADPH oxidase, increases reactive oxygen species, and
results in decreased NO bioavailability. In the current study,
NO production did not further increase with the combined
losartan and insulin treatment, which is consistent with the
findings that the increases in MBV and MBF were not sta-
tistically different between the two groups.
According to the Fick principle, increases in the endo-
thelial exchange surface area between the plasma and the
interstitial compartments in muscle could significantly in-
crease the delivery of insulin to the muscle microvascu-
lature and facilitate its transfer to the interstitial space and
enhance its metabolic action. Our observation that insulin-
stimulated glucose disposal and muscle Akt phosphory-
lation, two major indices of insulin metabolic actions in
muscle, closely parallel the changes in insulin-mediated
FIG. 7. AT2R blockade decreases skeletal muscle
125
I-insulin uptake.
Five minutes after bolus injection of
125
I-insulin (1.5 mCi i.v.), blood
and skeletal muscle samples were collected, and intact
125
I-insulin
was determined after trichloroacetic acid precipitation. A: Fraction of
plasma-intact
125
I-insulin. B: Muscle 125I-insulin uptake. n = 4–6. Com-
pared with saline, *P < 0.05.
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microvascular recruitment and NO production, and muscle
insulin uptake strongly supports this concept. Indeed,
PD123319 superimposing on insulin infusion decreased all
these major end points in the current study. The abroga-
tion of insulin-induced microvascular recruitment with
PD123319 infusion most likely resulted in a decreased in-
sulin delivery and uptake in the muscle because it is in the
microvasculature where insulin uptake takes place and
decreased exchange surface area could significantly de-
crease muscle insulin uptake. The decreases in NO pro-
duction and Akt phosphorylation with PD123319 infusion
are likely secondary to decreased stimulation of the AT2R
by ANG II and insulin receptor by insulin on the endo-
thelium (for NO) and decreased insulin delivery to the
muscle (for p-Akt).
In conclusion, both AT1Rs and AT2Rs regulate insulin’s
microvascular and metabolic actions in muscle. Our cur-
rent findings strongly suggest that ANG receptors affect
insulin sensitivity in vivo via modulating microvascular
perfusion. This is an important finding because changes in
the microvascular endothelial surface area significantly
affects insulin delivery to and action in muscle (2). Addi-
tional studies are needed to define the underlying mole-
cular mechanisms. Although AT1R activity restrains muscle
metabolic responses to insulin via decreased muscle mi-
crovascular recruitment and insulin delivery, AT2R activity is
required for normal muscle microvascular and metabolic
responses to insulin. Thus, pharmacologic manipulation
aimed at increasing the AT2R-to-AT1R activity ratio may af-
ford potential to improve muscle insulin sensitivity and
glucose metabolism and to reduce the cardiovascular com-
plications associated with diabetes and insulin resistance.
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